Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy.
C. Suzuki
No relevant relationships to disclose
L. Blomqvist
No relevant relationships to disclose
A. Sundin
No relevant relationships to disclose
P. Bystrom
No relevant relationships to disclose
A. Berglund
No relevant relationships to disclose
H. Jacobsson
No relevant relationships to disclose
P. Nygren
No relevant relationships to disclose
B. Glimelius
Research Funding - Merck; Pfizer